ZYBT · Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited (ZYBT) reported challenging FY2025 results ending December 31, 2025, with revenue of $116.4 million, down 37.6% from $186.4 million in FY2024. This decline stems from the company's sales model, where the operating entity maintains long-term written agreements typically lasting one year or brief purchase order-based arrangements with distributors, all calibrated to distributor customer demand. Production and inventory stocking align directly with market demand, received orders, planned orders, production capacity, and distributor procurement signals, explaining the topline contraction as these demand factors shifted year-over-year.

Operating income deteriorated sharply to a -$70.5 million loss, a -528.9% change from $16.4 million profit, yielding an operating margin of -60.6%. The swing highlights operating leverage working against the company, where fixed or semi-variable costs amplified the impact of lower revenue and squeezed gross profit. Without granular expense breakdowns available, the result points to broader expense pressures in a lower-revenue environment, consistent with biotech operations balancing production runs of eight hours daily across 280-320 days annually.

Net income followed suit, posting a -$69.8 million loss versus $11.3 million profit prior year (-717.0% change). This outcome reinforces the period's profitability challenges, driven by the revenue decline and margin contraction without offsetting income sources detailed in the statements.

Despite losses, cash generation remained positive, with net cash provided by operating activities at $13.3 million (down from $41.0 million) and capital expenditures reduced to $1.0 million from $13.6 million, delivering $12.3 million in free cash flow. Lower capex signals capital discipline, preserving liquidity as the company navigates headwinds from demand-based sales and production.

Looking ahead, management anticipates significant R&D expense growth to pursue new product development, existing product enhancements, and additional regulatory approvals. R&D costs are expensed as incurred due to unreliable measurement of future benefits and uncertain outcomes, positioning these investments as a long-term innovation driver. Operations continue stably with demand-responsive production, while ongoing PCAOB access demands for China/Hong Kong audit firms add external oversight context.